Varian nets FDA breakthrough nod for radioablation unit

By staff writers

May 28, 2021 -- Radiation oncology vendor Varian Medical Systems has garnered a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its cardiac radioablation system.

Varian said it's currently developing the system as a noninvasive therapy for select patients with refractory ventricular tachycardia. Unlike conventional catheter ablation for ventricular tachycardia, Varian's system targets and delivers ablative energy across the full thickness of the myocardium, according to the Siemens Healthineers company.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking